CNS Pharmaceuticals, Inc.
CNSP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001729427
In the last 90 days, CNS Pharmaceuticals, Inc. insiders filed 1 open-market purchase and 0 sales; 11 institutions reported holding it in 13F filings for Q2 2026, worth $1.34M in total; no superinvestor holds it.
Q3 2024 vs. Q2 2024
How the institutions holding CNS Pharmaceuticals, Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Q3 2024 | Change |
|---|---|---|---|
| Holders | 10 | 14 | +4 |
| Shares | 144.2K | 576.2K | +432.1K (+299.7%) |
| Value | $227.8K | $75.3K | −$152.5K (−67.0%) |
New holders (7)
Institutions that held CNS Pharmaceuticals, Inc. at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Geode Capital Management, LLC | 203,180 | $26.5K | 0.00% |
| Virtu Financial LLC | 122,876 | $16.0K | 0.00% |
| Goldman Sachs Group Inc | 28,197 | $3.68K | 0.00% |
| Jane Street Group, LLC | 23,160 | $3.02K | 0.00% |
| Aspire Private Capital, LLC | 400 | $52 | 0.00% |
| Danske Bank A/S | 2 | $0 | 0.00% |
| Northwestern Mutual Wealth Management Co | 1 | $0 | 0.00% |
Sold out (3)
Institutions that held CNS Pharmaceuticals, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Anson Funds Management LP | 141,398 | $223.4K |
| Morgan Stanley | 2 | $3 |
| FMR LLC | 1 | $2 |